Pharmaceutical - Incyte

Filter

Current filters:

Incyte

Popular Filters

Bristol-Myers and Incyte sign up to evaluate combo regimen of two immunotherapies

27-05-2014

US pharma major Bristol-Myers Squibb and Incyte Corp have set up a clinical trial collaboration to evaluate…

Bristol-Myers SquibbINCB24360IncyteLicensingnivolumabOncologyPharmaceuticalResearch

MedImmune and Incyte to collaborate on immunotherapy

MedImmune and Incyte to collaborate on immunotherapy

14-05-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaBahija JallalIncyteL1LicensingMajorMedImmuneOncologyPharmaceuticalTumorTumorsUKUSA

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

07-03-2014

Swiss pharma major Novartis today announced positive results from a pivotal Phase III trial of Jakavi…

IncyteJakaviNovartisOncologyPharmaceuticalRare diseasesRegulationResearch

Herve Hoppenot quits Novartis to join Incyte

Herve Hoppenot quits Novartis to join Incyte

13-01-2014

Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology,…

BoardroomIncyteManagementNovartisPharmaceutical

Incyte soars on positive mid-stage ruxolitinib trial results

22-08-2013

Shares of US drug developer Incyte Corp (Nasdaq: INCY) leapt 21% to $32.55 in premarket trading yesterday…

IncyteJakafiOncologyPharmaceuticalResearchruxolitinib

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

29-08-2012

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

Parexel

Parexel

Back to top